The impact of changing pathogens of serious infections in hospitalized patients

Clinical Infectious Diseases

Volumn 31, Issue SUPPL. 4, 2000, Pages

  McGowan J E , Jr ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; CLINDAMYCIN; LEVOFLOXACIN; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL MUTATION; BACTERIAL VIRULENCE; CLONOGENESIS; DRUG CHOICE; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS INFECTION;

BACTERIA; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DELIVERY OF HEALTH CARE; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; HUMANS;

EID: 0034458490     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/314077     Document Type: Review

References (75)

1. Consequences of increasing resistance to antimicrobial agents
2. Drug resistance and nosocomial infections: Epidemiology and prevention strategies
3. Emerging nosocomial infections and antimicrobial resistance
4. Epidemiology of drug resistance: Implications for a post-antimicrobial era
5. Antibiotic-resistant bacteria and health care systems - Four steps for effective response
6. The threat of vancomycin resistance
7. Epidemiology and prevention of nosocomial infections
8. New resistance in Staphylococcus aureus
9. Staphylococci vs. glycopeptides - How much are the battle lines changing?
10. Staphylococcus aureus with reduced susceptibility to vancomycin - Illinois, 1999
11. Vancomycin resistance among epidemic strains of methicillin-resistant Staphylococcus aureus in England and Wales
12. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides
13. Laboratory capacity to detect antimicrobial resistance, 1998
14. Vancomycin-resistant Staphylococcus aureus: Infection control considerations
15. Emergence of vancomycin resistance in Staphylococcus aureus
16. National Nosocomial Infections Surveillance (NNIS) System. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) in the United States, 1975-1996
17. Living with methicillin-resistant Staphylococcus aureus: A 7-year experience with endemic MRSA in a university hospital
18. Control of antimicrobial resistance in the health care system
19. Community-acquired methicillin-resistant Staphylococcus aureus in hospitalized adults and children without known risk factors
20. True community-acquired methicillin-resistant Staphylococcus aureus bacteremia
21. Prevalence of methicillin-resistant Staphylococcus aureus in a dermatology outpatient population
22. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified pre-disposing risk
23. Community strain of methicillin-resistant Staphylococcus aureus involved in a hospital outbreak
24. Increase in community-acquired methicillin-resistant Staphylococcus aureus in children
25. Community-acquired methicillin-resistant Staphylococcus aureus and familial transmission
26. Predisposing conditions, clinical presentation, and outcome of community-acquired Staphylococcus aureus bacteremia
27. Clinical and molecular epidemiology of community-acquired methicillin-resistant Staphylococcus aureus (MRSA) in adults, 1989-98
28. Risk factors for methicillin resistance in community-acquired Staphylococcus aureus bacteremia
29. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus - Minnesota and North Dakota, 1997-1999
30. Methicillin-resistant Staphylococcus aureus carriage in a child care center following a case of disease
31. Cross-Canada spread of methicillin-resistant Staphylococcus aureus via transplant organs
32. Community-acquired methicillin-resistant Staphylococcus aureus infections - Where do we go from here?
33. Recommendations for preventing the spread of vancomycin resistance
34. Penicillin-resistant Streptococcus pneumoniae increasingly threatens the patient and challenges the physician
35. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-98
36. Geographic variation in penicillin resistance in Streptococcus pneumoniae - Selected sites, United States, 1997
37. Resistance surveillance of Streptococcus pneumoniae, Haemophilus pneumoniae, and Moraxella catarrhalis isolated in the United States, 1997-1998
38. Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain. Results of a 1-year (1996-1997) multicenter surveillance study
39. Nosocomial penicillin-resistant pneumococcal infections at a midwestern university hospital
40. An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents
41. Drug-resistant Streptococcus pneumoniae: Rational antibiotic choices
42. Pneumococcal pneumonia in adults treated at University of Kentucky Medical Center. 1995-1998: Implications of pathogen resistance
43. Performance standards for antimicrobial susceptibility testing: 10th informational supplement
44. Emergence of vancomycin tolerance in Streptococcus pneumoniae
45. Antibiotic resistance. A vancomycin surprise
46. The microbial genetics of antibiotic cycling
47. The origins and molecular basis of antibiotic resistance
48. Epidemiology and molecular biology of antimicrobial resistance in bacteria
49. Regional dissemination of vancomycin-resistant enterococci resulting from interfacility transfer of colonized patients
50. vanA and vanB incorporate into an endemic ampicillin-resistant vancomycin-sensitive Enterococcus faecium strain: Effect on interpretation of clonality
51. In vitro exchange of fluoroquinolone resistance determinants between Streptococcus pneumoniae and viridans streptococci and genomic organization of the parE-parC region in Streptococcus mitis
52. Plasmid mediated coresistance to streptogramins and vancomycin in Enterococcus faecium HM1032
53. In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae
54. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa
55. Rapid emergence of resistant coagulase-negative staphylococci on the skin after antibiotic prophylaxis
56. Regional dissemination and control of epidemic methicillin-resistant Staphylococcus aureus
57. Assessment of bacterial crosstransmission as a cause of infections in patients in intensive care units
58. The changing molecular epidemiology and establishment of endemicity of vancomycin resistance in enterococci at one hospital over a 6-year period
59. Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: Trend analysis
60. The Alexander Project 1996-1997: Latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections
61. Changing epidemiology of infections in patients with neutropenia and cancer: Emphasis on gram-positive and resistant bacteria
62. Molecular characterization of multidrug resistance in Streptococcus mitis
63. Macrolide resistance in Streptococcus pneumoniae
64. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995
65. Metallo-β-lactamases: A class apart
66. Antibiotic cycling and marketing into the 21st century: A perspective from the pharmaceutical industry
67. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections
68. Novelties in the field of anti-infectives in 1998
69. A novel antimicrobial agent joins the battle against resistant bacteria
70. Activity of linezolid against multi-resistant gram-positive bacteria from diverse hospitals in the United Kingdom
71. What can be done about resistance to antibiotics?
72. The epidemiology of antibiotic resistance in hospital acquired infections: Problems and possible solutions
73. Optimal use of modern antibiotics: Emerging trends
74. Strategies for study of the role of cycling on antimicrobial use and resistance